Targeting DNA methyltransferases in non-small-cell lung cancer
- PMID: 33486076
- DOI: 10.1016/j.semcancer.2021.01.005
Targeting DNA methyltransferases in non-small-cell lung cancer
Abstract
Despite the advances in treatment using chemotherapy or targeted therapies, due to static survival rates, non-small cell lung cancer (NSCLC) is the major cause of cancer-related deaths worldwide. Epigenetic-based therapies have been developed for NSCLC by targeting DNA methyltransferases (DNMTs) and histone-modifying enzymes. However, treatment using single epigenetic agents on solid tumours has been inadequate; whereas, treatment with a combination of DNMTs inhibitors with chemotherapy and immunotherapy has shown great promise. Dietary sources of phytochemicals could also inhibit DNMTs and cancer stem cells, representing a novel and promising way to prevent and treat cancer. Herein, we will discuss the different DNMTs, DNA methylation profiling in NSCLC as well as current demethylating agents in ongoing clinical trials. Therefore, providing a concise overview of future developments in the field of epigenetic therapy in NSCLC.
Keywords: DNA methylation; DNA methyltransferases; Demethylating agents; Dietary phytochemicals; Non-small cell lung cancer.
Copyright © 2021 Elsevier Ltd. All rights reserved.
Similar articles
-
Epigenetic therapy approaches in non-small cell lung cancer: Update and perspectives.Epigenetics. 2016 Dec;11(12):858-870. doi: 10.1080/15592294.2016.1237345. Epub 2016 Nov 15. Epigenetics. 2016. PMID: 27846368 Free PMC article. Review.
-
Epigenetic-based therapies in cancer: progress to date.Drugs. 2011 Dec 24;71(18):2391-403. doi: 10.2165/11596690-000000000-00000. Drugs. 2011. PMID: 22141383 Review.
-
Epigenetic therapy in non-small-cell lung cancer: targeting DNA methyltransferases and histone deacetylases.Expert Opin Biol Ther. 2013 Sep;13(9):1273-85. doi: 10.1517/14712598.2013.819337. Epub 2013 Jul 17. Expert Opin Biol Ther. 2013. PMID: 23859704 Review.
-
The expression of DNA methyltransferases and methyl-CpG-binding proteins is not associated with the methylation status of p14(ARF), p16(INK4a) and RASSF1A in human lung cancer cell lines.Oncogene. 2002 Jul 18;21(31):4822-9. doi: 10.1038/sj.onc.1205581. Oncogene. 2002. PMID: 12101420
-
Epigenetic drug discovery: targeting DNA methyltransferases.J Biomol Screen. 2012 Jan;17(1):2-17. doi: 10.1177/1087057111421212. Epub 2011 Sep 30. J Biomol Screen. 2012. PMID: 21965114 Review.
Cited by
-
Role of miR-26b in regulating non-small cell lung cancer progression via targeting RCN1.J Thorac Dis. 2025 Jun 30;17(6):3873-3885. doi: 10.21037/jtd-24-999. Epub 2025 Jun 3. J Thorac Dis. 2025. PMID: 40688319 Free PMC article.
-
Mass Spectrometry-Based Proteomics: Analyses Related to Drug-Resistance and Disease Biomarkers.Medicina (Kaunas). 2023 Sep 27;59(10):1722. doi: 10.3390/medicina59101722. Medicina (Kaunas). 2023. PMID: 37893440 Free PMC article. Review.
-
HDAC inhibitor ITF2357 reduces resistance of mutant-KRAS non-small cell lung cancer to pemetrexed through a HDAC2/miR-130a-3p-dependent mechanism.J Transl Med. 2023 Feb 15;21(1):125. doi: 10.1186/s12967-023-03973-3. J Transl Med. 2023. PMID: 36793108 Free PMC article.
-
Integrated Bioinformatic Analysis Identifies TIPIN as a Prognostic Biomarker in Hepatocellular Carcinoma.Dis Markers. 2022 Jan 17;2022:5764592. doi: 10.1155/2022/5764592. eCollection 2022. Dis Markers. 2022. PMID: 35082931 Free PMC article.
-
The interplay between driver mutation and oxidative stress in colorectal cancer: from pathogenesis to therapeutics.J Transl Med. 2025 Jun 9;23(1):635. doi: 10.1186/s12967-025-06640-x. J Transl Med. 2025. PMID: 40490762 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical